Rubius Therapeutics Inc (NASDAQ:RUBY) Director Robert Langer sold 7,500 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $14.94, for a total value of $112,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ RUBY opened at $15.08 on Friday. Rubius Therapeutics Inc has a fifty-two week low of $12.70 and a fifty-two week high of $27.73. The company’s 50-day moving average is $14.66. The company has a current ratio of 18.64, a quick ratio of 18.64 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.21 billion and a PE ratio of -6.64.
Rubius Therapeutics (NASDAQ:RUBY) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). Analysts expect that Rubius Therapeutics Inc will post -1.84 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of RUBY. BlackRock Inc. raised its stake in shares of Rubius Therapeutics by 52.9% during the fourth quarter. BlackRock Inc. now owns 2,430,505 shares of the company’s stock valued at $39,083,000 after purchasing an additional 840,707 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Rubius Therapeutics during the first quarter valued at about $14,995,000. FMR LLC raised its stake in shares of Rubius Therapeutics by 8.9% during the first quarter. FMR LLC now owns 7,019,730 shares of the company’s stock valued at $127,057,000 after purchasing an additional 573,662 shares in the last quarter. Nikko Asset Management Americas Inc. bought a new stake in shares of Rubius Therapeutics during the first quarter valued at about $9,370,000. Finally, Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Rubius Therapeutics during the first quarter valued at about $9,083,000. Institutional investors and hedge funds own 93.75% of the company’s stock.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.